Dr. Mark Bear 1:1 with FRAXA – Developing Arbaclofen for Fragile X
Research Updates with FRAXA
Seven years ago, arbaclofen (STX209) was pulled from development, disappointing families around the US. Now MIT professor and FRAXA Investigator Dr. Mark Bear has founded Allos Pharma to bring it back. Dr. Bear sat down with FRAXA co-founder Katie Clapp to share the story and next steps.
Science On Screen Presents: Dr. Mark Bear
a talk at the Martha's Vineyard Film Society
Dr. Mark Bear discusses the feasibility of a "neuralyzer" as seen in the Men In Black films to the Martha's Vineyard Film Society as part of their Science On Screen series.
Beckman Foundation Names Mark Bear, Ph.D., of the Massachusetts Institute of Technology as 2018 Beckman-Argyros Vision Research Award Winner
from the Arnold and Mabel Beckman Foundation
The Arnold and Mabel Beckman Foundation today announced its 2018 Beckman-Argyros Vision Research Award winner is Dr. Mark Bear, Picower Professor of Neuroscience at the Massachusetts Institute of Technology.…
A Path from Genes to Treatment of Fragile X Syndrome and Related Developmental Brain Disorders (October 19, 2017)
from the Fralin Biomedical Research Institute